NCT04517357

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

A Phase 2 Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in the Treatment of Relapsed Ovarian Cancer Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, open-label, 2-arm Phase 2 study to evaluate the efficacy and safety of Fluzoparib with Apatinib versus Fluzoparib alone, as treatment, in relapsed ovarian cancer patients. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 2 portion of the study.

Conditions

• Relapsed Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Fluzoparib+Apatinib	Fluzoparib-Apatinib combination
DRUG	Fluzoparib	Fluzoparib monotherapy
DRUG	Fluzoparib+Apatinib	Fluzoparib-Apatinib combination

Timeline

• Start date: 2020-10-16
• Primary completion: 2023-11-30
• Completion: 2024-11-01
• First posted: 2020-08-18
• Last updated: 2025-02-24

Locations

1 site across 1 country: China